TCDA News and Press, Tricida Inc. From 08/08/22

Webcast Today at 4:30 pm Eastern Time Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three and six months ended June 30, 2022 and provided an update on key initiatives. Business Update Tricida announced in May 2022 that it stopped its VA...

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its second quarter 2022 financial results after the close of market on Monday, August 8, 2022. Tricida will host a webcast and conference call at 4:30 pm East...

Gainers: Avadel Pharmaceuticals ( AVDL ) +5% . Cerence ( CRNC ) +4% . Tricida ( TCDA ) +3% . Plains All American Pipeline ( PAA ) +3% . Vir Biotechnology ( VIR ) +2% . Losers: Codexis ( CDXS ) -18% . 10x Genom...

Tricida (TCDA) +5.22% disclose that its owner Venrock Healthcare Capital Partners II, L.P purchase 190,871 shares of common stock. As per sec filings shares were purchased in the multiple transactions at price range of $8.73 to $9.50 for $1.7M For further details see: Tricida rise +5.22...

Tricida (NASDAQ:TCDA) said it is stopping its VALOR-CKD trial of veverimer for kidney disease early due to administrative reasons pursuant to a study protocol to allow for six months of financial runway after reporting top-line results, which is expected early in Q4 2022. "We have previo...

SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) announced today that as anticipated it is stopping its VALOR-CKD renal outcomes trial early for administrative reasons pursuant to the existing study protocol to allow for six months of financial...

Tricida, Inc. (TCDA) Q1 2022 Earnings Conference Call May 10, 2022 16:30 ET Company Participants Jackie Cossmon - Investor Relations Gerrit Klaerner - Founder, Chief Executive Officer and President Geoff Parker - Chief Operating Officer and Chief Financial Officer Conference Call Participants...

The following slide deck was published by Tricida, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Tricida, Inc. 2022 Q1 - Results - Earnings Call Presentation

Tricida press release (NASDAQ:TCDA): Q1 GAAP EPS of -$0.51 beats by $0.15. “We have seen a steady increase in primary endpoint events in the VALOR-CKD trial and continue to believe that we will obtain interpretable data to evaluate how treatment with veverimer impacts slowing of CKD pr...

SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three months ended March 31, 2022 and provided an update on key initiatives. Business Update Tricida continued to execute on the conduct ...